Image Place holder

Rachel Voss, MD, MPH

Specialty: Surgery
Program: Sarcoma

Overview

Cancer Focus: Adrenal Carcinoma, Adrenal Nodule/Mass, GIST (Gastrointestinal Stromal Tumor), Sarcoma, Small Intestine Cancer, Stomach (Gastric) Cancer

  Dr. Voss received an MD from the Ohio State University College of Medicine and an MPH in Epidemiology from the University of Texas Health Sciences Center at Houston. She completed a General Surgery Residency at the University of California San Diego Medical Center, and most recently completed a Complex General Surgical Oncology Fellowship at the University of Texas MD Anderson Cancer Center.  Dr. Voss’s clinical interests include extremity sarcomas, complex retroperitoneal and abdominal sarcomas, GISTs, and adrenal tumors (both benign and malignant). She offers posterior retroperitoneoscopic adrenalectomy (PRA) procedures for patients with adrenal tumors, which is a minimally-invasive approach to adrenalectomy performed through the back muscles. This procedure is ideal for patients with prior abdominal surgery or for those who need procedures on both the left and right adrenal glands at the same time. She is the only surgeon at Moffitt and one of the few in the Tampa area that offers this approach. Her research interests include health services research, focusing on the analysis of both institutional and national databases such as the National Cancer Database (NCDB) and patient-reported outcomes. Additionally, she has a specific research focus on the adequate delivery of surgical care nationally in the areas of extremity sarcomas and GISTs to identify gaps in care delivery in the U.S.    


Education & Training

Fellowship:

  • University of Texas MD Anderson Cancer Center - Complex General Surgical Oncology

Residency:

  • University of California - General Surgery

Medical School:

  • Ohio State University - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Tseng WW, Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladdy RA, Gyorki DE, Fairweather M, Lee KW, Albertsmeier M, van Houdt WJ, Fau M, Nessim C, Grignani G, Cardona K, Quagliuolo V, Grignol V, Farma JM, Pennacchioli E, Fiore M, Hayes A, Tzanis D, Skoczylas J, Almond ML, Mullinax JE, Johnston W, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Desai A, Voss R, Sanfilippo R, Jones RL, Baldini EH, Wagner AJ, Catton CN, Stacchiotti S, Thway K, Roland CL, Raut CP, Gronchi A. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol. 2022 Nov.29(12):7335-7348. Pubmedid: 35767103.
  • Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Ann Surg Oncol. 2022 Mar. Pubmedid: 35254579.
  • Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Ann Surg Oncol. 2022 Feb. Pubmedid: 35224688.
  • Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2021 Dec.28(13):9159-9168. Pubmedid: 34046772.
  • Voss RK, Massarweh NN, Roland CL. ASO Author Reflections: Imatinib Use Remains Inadequate for High-Risk GIST Patients. Ann Surg Oncol. 2021 Dec.28(13):9169-9170. Pubmedid: 34018084.
  • Voss RK, Massarweh NN, Chiang YJ, Somaiah N, Feig BW, Roland CL. ASO Visual Abstract: National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2021 Dec.28(Suppl 3):457. Pubmedid: 34050428.
  • Voss RK, Lin JC, Roper MT, Al-Temimi MH, Ruan JH, Tseng WH, Tam M, Sherman MJ, Klaristenfeld DD, Tomassi MJ. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision. Dis Colon Rectum. 2020 Apr.63(4):427-440. Pubmedid: 31996583.
  • Marcus RK, Lillemoe HA, Rice DC, Mena G, Bednarski BK, Speer BB, Ramirez PT, Lasala JD, Navai N, Williams WH, Kim BJ, Voss RK, Gottumukkala VN, Aloia TA. Determining the Safety and Efficacy of Enhanced Recovery Protocols in Major Oncologic Surgery: An Institutional NSQIP Analysis. Ann Surg Oncol. 2019 Mar.26(3):782-790. Pubmedid: 30627879. Pmcid: PMC6878764.
  • Voss RK, Ward EP, Ojeda-Fournier H, Blair SL. Doppler Ultrasound-Visible SignalMark Microspheres are Better Identified than HydroMARK® Clips in a Simulated Intraoperative Setting in Breast and Lung Tissue. Ann Surg Oncol. 2018 Nov.25(12):3740-3746. Pubmedid: 30178390. Pmcid: PMC6277056.
  • Stucky CH, Cromwell KD, Voss RK, Chiang YJ, Woodman K, Lee JE, Cormier JN. Surgeon symptoms, strain, and selections: Systematic review and meta-analysis of surgical ergonomics. Ann Med Surg (Lond). 2018 Mar.27:1-8. Pubmedid: 29511535. Pmcid: PMC5832650.
  • Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol. 2018 Jan.44(1):170-177. Pubmedid: 29208319. Pmcid: PMC5747371.
  • Voss RK, Grubbs EG. Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness". J Clin Endocrinol Metab. 2017 Sep.102(9):3559. Pubmedid: 28911160.
  • Voss RK, Chiang YJ, Torres KE, Guadagnolo BA, Mann GN, Feig BW, Cormier JN, Roland CL. Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma. Ann Surg Oncol. 2017 Oct.24(11):3271-3278. Pubmedid: 28741122. Pmcid: PMC5693748.
  • Voss RK, Chiang YJ, Cromwell KD, Urbauer DL, Lee JE, Cormier JN, Stucky CH. Do No Harm, Except to Ourselves? A Survey of Symptoms and Injuries in Oncologic Surgeons and Pilot Study of an Intraoperative Ergonomic Intervention. J Am Coll Surg. 2017 Jan.224(1):16-25.e1. Pubmedid: 27693681.
  • Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 Aug.102(8):2807-2813. Pubmedid: 28609830. Pmcid: PMC5546858.
  • Voss RK, Woods TN, Cromwell KD, Nelson KC, Cormier JN. Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis. Patient Relat Outcome Meas. 2015 Nov.6:229-242. Pubmedid: 26609248. Pmcid: PMC4644158.
  • Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Stewart BR, Shaitelman SF, Cormier JN. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol. 2015 Dec.112(8):834-840. Pubmedid: 26477877. Pmcid: PMC4715673.

Patient Comments
Overall Satisfaction
4.8

60 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments